Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.

CONCLUSIONS: Our findings demonstrate that somatic mutations in multiple myeloma can be immunogenic and induce neoantigen-specific T-cell activation that is associated with antitumor activity in vitro and clinical response in vivo. Our results provide the foundation for using neoantigen targeting strategies such as peptide vaccines in future trials for patients with multiple myeloma.
PMID: 31857430 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 18, 2019 Category: Cancer & Oncology Authors: Perumal D, Imai N, Laganà A, Finnigan J, Melnekoff D, Leshchenko VV, Solovyov A, Madduri D, Chari A, Cho HJ, Dudley JT, Brody JD, Jagannath S, Greenbaum B, Gnjatic S, Bhardwaj N, Parekh S Tags: Clin Cancer Res Source Type: research